Phenotypic plasticity has emerged as a major contributor to intra-tumoral heterogeneity and
treatment resistance in cancer. Increasing evidence shows that glioblastoma (GBM) cells …

Cancer stem cells (CSCs), also known as tumor‐initiating cells (TICs), are suggested to be
responsible for drug resistance and cancer relapse due in part to their ability to self‐renew …

Glioblastoma is an aggressive and heterogeneous tumor in which glioblastoma stem cells
(GSCs) are at the apex of an entropic hierarchy and impart devastating therapy resistance …

The identity and unique capacity of cancer stem cells (CSC) to drive tumor growth and
resistance have been challenged in brain tumors. Here we report that cells expressing CSC …

Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy
for glioblastoma multiforme (GBM) and astrocytoma. A majority of patients do not respond to …

The complexity of glioblastoma multiforme, the most common and lethal variant of gliomas,
is reflected by cellular and molecular heterogeneity at both the inter-and intra-tumoural …

Glioblastoma is the most common and lethal primary malignant brain tumor in adults.
Patients die from recurrent tumors that have become resistant to therapy. New strategies are …

Glioblastoma (GBM) is the highest-grade form of glioma, as well as one of the most
aggressive types of cancer, exhibiting rapid cellular growth and highly invasive behavior …

Tumour-associated macrophages (TAMs) are enriched in glioblastoma multiformes (GBMs)
that contain glioma stem cells (GSCs) at the apex of their cellular hierarchy. The correlation …

Rationale: In the glioblastoma (GBM) microenvironment, tumor-associated macrophages
(TAMs) are prominent components and facilitate tumor growth. The exact molecular …